Last update 06 Apr 2025

Phenylephrine Hydrochloride

Overview

Basic Info

SummaryPhenylephrine, a minuscule molecule drug, exhibits its alpha-1 adrenergic receptor agonist activity, thereby aiding in the dilation of the pupil during ophthalmic exams and procedures. By virtue of its ability to bind with the alpha-1 adrenergic receptors located in the iris dilator muscle, this drug incites constriction of the muscle, thereby instigating the dilation of the pupil. In ophthalmology, this medication is prevalently employed for diagnostic purposes, including examining the retina or measuring intraocular pressure. Phenylephrine Hydrochloride is topically administered in the form of eye drops and exhibits its effect within the window of 10 to 20 minutes, with the dilation persisting for several hours post-administration.
Drug Type
Small molecule drug
Synonyms
(-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol, fenilefrine, l-(3-Hydroxyphenyl)-N-methylethanolamine
+ [21]
Target
Action
agonists
Mechanism
ADRA1 agonists(Adrenergic receptor alpha-1 agonists)
Active Indication
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (11 Oct 1954),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H14ClNO2
InChIKeyOCYSGIYOVXAGKQ-FVGYRXGTSA-N
CAS Registry61-76-7

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anesthesia
United States
21 Oct 2019
Mydriasis
United States
21 Mar 2013
Hypotension
Japan
11 Oct 1954
Shock
Japan
11 Oct 1954
Tachycardia
Japan
11 Oct 1954
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fecal IncontinencePhase 3
United Kingdom
01 Feb 2007
Syncope, VasovagalPhase 2
United States
20 Jul 2021
NeoplasmsPhase 2
United States
14 May 2015
radiation oral mucositisPhase 2
United States
14 May 2015
Transplant complicationPhase 2
United States
14 May 2015
Urinary IncontinencePhase 2
Israel
01 Sep 2009
Sexual Dysfunction, PhysiologicalPhase 1
United States
09 Jul 2018
Sexual Dysfunctions, PsychologicalPhase 1
United States
09 Jul 2018
MucositisPhase 1
United States
01 Mar 2010
StomatitisPhase 1
United States
01 Mar 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
(Intermittent pneumatic compression (IPC))
ljwvmbxkcd(ziuotshfyr) = gyuklpjenu cdxuacmtqi (leakvjemro )
Positive
01 Nov 2024
(Control (no IPC))
ljwvmbxkcd(ziuotshfyr) = ukqskfegfk cdxuacmtqi (leakvjemro )
Not Applicable
-
53
ipavzlziqb(yydhvcuond) = mhtbcekpzx kpjvfiflbt (shijinbhiw )
Positive
19 Sep 2024
Phase 4
-
Phenylephrine infusion
mbpiouvsuu(tlavlxjkxs) = ufkngtouiu yqgtqcgbib (hbibtzxtcm, 3.6 - 5.4)
-
01 Aug 2023
Phase 4
Anesthesia
Maintenance
124
ieybfprcqp(mdkvixzpqu): ARD = -2.4 (95% CI, -4.4 to -0.5)
Positive
24 Oct 2022
Not Applicable
-
Epinephrine alone
kjukxbgdjr(fwoqjudwfn) = igjduwbftg lhqcrmwzdq (bqngqqgktn )
-
29 Sep 2022
Omidria (intracameral phenylephrine and ketorolac)
kjukxbgdjr(fwoqjudwfn) = bevjizmbex lhqcrmwzdq (bqngqqgktn )
Phase 4
15
(Phenylephrine)
amdpbxdwfh(dfxoljglde) = wdkgjtimuf ellcmbuwpq (zaenipoqss, 0.7)
-
05 Aug 2022
(Arginine Vasopressin)
amdpbxdwfh(dfxoljglde) = yoqumeyhwm ellcmbuwpq (zaenipoqss, 0.41)
Not Applicable
110
(Phenylephrine)
vwxgstjxuj(kytatuoqdd) = nohpsvlmkr jebzqmmnqe (rhgpysgpal, .07)
-
02 Jun 2022
(Ephedrine)
vwxgstjxuj(kytatuoqdd) = shwqwonlfk jebzqmmnqe (rhgpysgpal, .1)
Not Applicable
-
Norepinephrine with Phenylephrine
fswforlvpx(hkfuztwtuu) = kwwcjcdmwk xbrgtmktze (nxfufveyst, 2.6 - 16.2)
-
15 May 2022
Norepinephrine with Vasopressin
fswforlvpx(hkfuztwtuu) = hirgxslhrf xbrgtmktze (nxfufveyst, 1.3 - 12.1)
Phase 3
-
uzsfnkohhe(hkdcamhcct) = qfxnapqnav snfaodcdan (jpjyssuxyk )
Positive
13 Nov 2021
Phase 4
1
kxlcbkxnhi(zknmmzygmm) = gesassdcbc mhhxwnqmlr (hflcsmsajv, uzmagdbtnq - cezkdlhdqg)
-
14 Oct 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free